Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Clinical trial NCT06642545 · RECRUITING
Trial details
- NCT number
- NCT06642545
- Sponsor
- RemeGen Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-10
- Primary completion
- 2026-10-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.